Collegium Pharmaceutical, Inc. (COLL) 10-Year Financial Performance & Capital Metrics

COLL • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsPain Management

AboutCollegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Show more

Revenue $631M +11.4%
EBITDA $339M +7.2%
Net Income $69M +43.7%
EPS (Diluted) 1.86 +44.2%
Gross Margin 59.76% +3.8%
EBITDA Margin 53.69% -3.8%
Operating Margin 26.91% -8.7%
Net Margin 10.96% +29.0%
ROE 32.62% +32.2%
ROIC 15.46% -16.0%
Debt/Equity 3.75 +8.8%
Interest Coverage 2.30 +14.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓FCF machine: 32.2% free cash flow margin
✓Momentum leader: RS Rating 83 (top 17%)
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 16.3%
✓Share count reduced 3.3% through buybacks

✗Weaknesses

✗High debt to equity ratio of 3.8x

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y16.31%

3Y31.63%

TTM26.34%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-1.1%

TTM-34.03%

EPS CAGR

10Y-

5Y-

3Y0%

TTM-30.88%

ROCE

10Y Avg-17.42%

5Y Avg14.82%

3Y Avg15.89%

Latest18.47%

Peer Comparison

Pain Management

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
COLLCollegium Pharmaceutical, Inc.	1.48B	46.90	25.22	11.41%	7.72%	21.27%	13.71%	3.75
PRFXPainReform Ltd.	3.21M	0.82	-0.03			-48.4%		0.02
PCRXPacira BioSciences, Inc.	848.72M	20.65	-9.60	3.85%	2.99%	2.95%	21.06%	0.82
APUSApimeds Pharmaceuticals US, Inc	21.76M	1.73	-15.73			-63.2%
ASRTAssertio Holdings, Inc.	71.42M	11.13	-48.39	-17.83%	-21.06%	-27.34%	36.98%	0.33

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	1.71M	28.48M	280.41M	296.7M	310.02M	276.87M	463.93M	566.77M	631.45M
Revenue Growth %	-	-	15.64%	8.85%	0.06%	0.04%	-0.11%	0.68%	0.22%	0.11%
Cost of Goods Sold+	171K	213K	2.6M	165.68M	193.66M	130.18M	126.25M	254.44M	240.6M	254.1M
COGS % of Revenue	-	0.12%	0.09%	0.59%	0.65%	0.42%	0.46%	0.55%	0.42%	0.4%
Gross Profit+	-171K	1.5M	25.88M	114.74M	103.04M	179.84M	150.62M	209.49M	326.17M	377.34M
Gross Margin %	-	0.88%	0.91%	0.41%	0.35%	0.58%	0.54%	0.45%	0.58%	0.6%
Gross Profit Growth %	-	9.76%	16.28%	3.43%	-0.1%	0.75%	-0.16%	0.39%	0.56%	0.16%
Operating Expenses+	26.91M	95.58M	101.33M	135.42M	126.79M	123.6M	132.99M	176.17M	159.21M	207.45M
OpEx % of Revenue	-	55.86%	3.56%	0.48%	0.43%	0.4%	0.48%	0.38%	0.28%	0.33%
Selling, General & Admin	18.93M	80.63M	92.76M	126.76M	116.45M	113.83M	118.96M	172.19M	159.21M	182.98M
SG&A % of Revenue	-	47.13%	3.26%	0.45%	0.39%	0.37%	0.43%	0.37%	0.28%	0.29%
Research & Development	7.97M	14.95M	8.57M	8.66M	10.34M	9.77M	9.45M	3.98M	0	0
R&D % of Revenue	-	8.74%	0.3%	0.03%	0.03%	0.03%	0.03%	0.01%	-	-
Other Operating Expenses	0	-94K	0	0	0	0	4.58M	0	0	24.47M
Operating Income+	-26.91M	-94.08M	-75.45M	-20.68M	-23.75M	56.23M	17.63M	33.32M	166.96M	169.9M
Operating Margin %	-	-54.99%	-2.65%	-0.07%	-0.08%	0.18%	0.06%	0.07%	0.29%	0.27%
Operating Income Growth %	-0.52%	-2.5%	0.2%	0.73%	-0.15%	3.37%	-0.69%	0.89%	4.01%	0.02%
EBITDA+	-26.74M	-93.43M	-74.85M	90.22M	-8.27M	117.78M	86.55M	172.26M	316.22M	339.06M
EBITDA Margin %	-	-54.6%	-2.63%	0.32%	-0.03%	0.38%	0.31%	0.37%	0.56%	0.54%
EBITDA Growth %	-0.53%	-2.49%	0.2%	2.21%	-1.09%	15.25%	-0.27%	0.99%	0.84%	0.07%
D&A (Non-Cash Add-back)	171K	655K	594K	110.91M	15.48M	61.55M	68.92M	138.94M	149.26M	169.16M
EBIT	-26.82M	-94.08M	-74.86M	-19M	-21.81M	56.46M	17.64M	34.37M	159.07M	172.54M
Net Interest Income+	0	-94K	582K	-18.44M	1.03M	-28.65M	-21M	-62.17M	-67.72M	-60M
Interest Income	0	0	582K	1.69M	1.94M	232K	12K	1.05M	15.62M	13.98M
Interest Expense	439K	94K	0	20.13M	909K	28.88M	21.01M	63.21M	83.34M	73.97M
Other Income/Expense	-348K	-94K	582K	-18.44M	1.03M	-28.65M	-21M	-62.17M	-91.23M	-71.33M
Pretax Income+	-27.25M	-94.18M	-74.86M	-39.13M	-22.72M	27.58M	-3.37M	-28.85M	75.73M	98.57M
Pretax Margin %	-	-55.04%	-2.63%	-0.14%	-0.08%	0.09%	-0.01%	-0.06%	0.13%	0.16%
Income Tax+	-91K	94K	0	0	0	830K	-74.89M	-3.85M	27.58M	29.38M
Effective Tax Rate %	1%	1%	1%	1%	1%	0.97%	-21.2%	0.87%	0.64%	0.7%
Net Income+	-27.25M	-94.18M	-74.86M	-39.13M	-22.72M	26.75M	71.52M	-25M	48.16M	69.19M
Net Margin %	-	-55.04%	-2.63%	-0.14%	-0.08%	0.09%	0.26%	-0.05%	0.08%	0.11%
Net Income Growth %	-0.52%	-2.46%	0.21%	0.48%	0.42%	2.18%	1.67%	-1.35%	2.93%	0.44%
Net Income (Continuing)	-27.25M	-94.18M	-74.86M	-39.13M	-22.72M	26.75M	71.52M	-25M	48.16M	69.19M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.01	-3.88	-2.47	-1.19	-0.24	0.76	1.86	-0.74	1.29	1.86
EPS Growth %	0.16%	-0.93%	0.36%	0.52%	0.8%	4.17%	1.45%	-1.4%	2.74%	0.44%
EPS (Basic)	-2.01	-3.88	-2.47	-1.19	-0.24	0.78	2.05	-0.74	1.60	2.14
Diluted Shares Outstanding	13.54M	24.26M	30.27M	32.95M	33.45M	35.15M	41.05M	33.83M	41.79M	40.42M
Basic Shares Outstanding	13.54M	24.26M	30.27M	32.88M	33.45M	34.41M	34.94M	33.83M	33.74M	32.27M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	96.88M	158.57M	133.48M	237.51M	255.72M	277.89M	315.54M	419.99M	537.6M	482.26M
Cash & Short-Term Investments	95.7M	153.22M	118.7M	146.63M	170.02M	174.12M	186.43M	173.69M	310.55M	162.76M
Cash Only	95.7M	153.22M	118.7M	146.63M	170.02M	174.12M	186.43M	173.69M	238.95M	70.56M
Short-Term Investments	0	0	0	0	0	0	0	0	71.6M	92.2M
Accounts Receivable	0	2.13M	9.97M	77.95M	72.95M	83.32M	105.84M	183.12M	179.53M	228.54M
Days Sales Outstanding	-	454.17	127.78	101.46	89.75	98.1	139.54	144.07	115.61	132.1
Inventory	0	1.32M	1.81M	7.82M	9.64M	15.61M	17.39M	46.5M	32.33M	35.56M
Days Inventory Outstanding	-	2.26K	255.01	17.22	18.17	43.78	50.29	66.71	49.05	51.08
Other Current Assets	558K	304K	456K	1.01M	141K	60K	27K	57K	93K	27.74M
Total Non-Current Assets+	835K	3.44M	2.08M	53.73M	50.58M	365.95M	376.53M	754.14M	605.71M	1.18B
Property, Plant & Equipment	738K	1.04M	1.83M	9.27M	20.9M	27.38M	27.14M	26.38M	22.01M	20.15M
Fixed Asset Turnover	-	1.65x	15.59x	30.24x	14.20x	11.32x	10.20x	17.59x	25.75x	31.34x
Goodwill	0	0	0	0	0	0	0	133.69M	133.86M	162.33M
Intangible Assets	0	2.1M	0	44.26M	29.5M	335.9M	268.72M	567.47M	421.71M	891.4M
Long-Term Investments	97K	97K	97K	0	0	0	0	0	0	0
Other Non-Current Assets	0	301K	161K	204K	178K	2.67M	2.63M	2.65M	1.87M	9.41M
Total Assets+	97.72M	162.02M	135.57M	291.25M	306.3M	643.84M	692.08M	1.17B	1.14B	1.66B
Asset Turnover	-	0.01x	0.21x	0.96x	0.97x	0.48x	0.40x	0.40x	0.50x	0.38x
Asset Growth %	18.2%	0.66%	-0.16%	1.15%	0.05%	1.1%	0.07%	0.7%	-0.03%	0.46%
Total Current Liabilities+	5.76M	22.93M	31.49M	187.48M	201.76M	239.45M	279.57M	433.73M	457.92M	509.51M
Accounts Payable	3.54M	9.11M	5.68M	12.15M	6.25M	10.02M	4.19M	3.49M	8.69M	3.93M
Days Payables Outstanding	7.55K	15.6K	799.48	26.77	11.77	28.08	12.11	5.01	13.19	5.65
Short-Term Debt	2.67M	2.67M	1.48M	1.64M	3.83M	47.49M	48.35M	162.5M	183.33M	64.58M
Deferred Revenue (Current)	-1000K	1000K	0	0	0	0	0	0	988K	0
Other Current Liabilities	661K	4.29M	18.21M	167.7M	5.7M	1.42M	851K	1.51M	253.91M	7.61M
Current Ratio	16.81x	6.92x	4.24x	1.27x	1.27x	1.16x	1.13x	0.97x	1.17x	0.95x
Quick Ratio	16.81x	6.86x	4.18x	1.23x	1.22x	1.10x	1.07x	0.86x	1.10x	0.88x
Cash Conversion Cycle	-	-12.89K	-416.7	91.91	96.15	113.79	177.71	205.76	151.48	177.53
Total Non-Current Liabilities+	6.88M	4.18M	7.16M	12.18M	17.11M	218.36M	209.58M	545.56M	489.96M	925.24M
Long-Term Debt	4.15M	1.48M	0	9.86M	7.67M	209.59M	201.63M	538.45M	483.84M	787.9M
Capital Lease Obligations	68K	34K	0	0	9.44M	8.77M	7.95M	7.11M	6.12M	5.54M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	676K	0	0	0	0	0	121.8M
Total Liabilities	12.65M	27.11M	31.49M	199.66M	218.87M	457.81M	489.15M	979.29M	947.88M	1.43B
Total Debt+	6.81M	4.15M	1.48M	11.5M	21.59M	266.58M	258.75M	709.17M	674.28M	859.3M
Net Debt	-88.88M	-149.08M	-117.22M	-135.13M	-148.43M	92.47M	72.32M	535.49M	435.34M	788.73M
Debt / Equity	0.08x	0.03x	0.01x	0.13x	0.25x	1.43x	1.28x	3.64x	3.45x	3.75x
Debt / EBITDA	-	-	-	0.13x	-	2.26x	2.99x	4.12x	2.13x	2.53x
Net Debt / EBITDA	-	-	-	-1.50x	-	0.79x	0.84x	3.11x	1.38x	2.33x
Interest Coverage	-61.29x	-1000.87x	-	-1.03x	-26.13x	1.95x	0.84x	0.53x	2.00x	2.30x
Total Equity+	85.07M	134.91M	104.08M	91.58M	87.43M	186.03M	202.93M	194.84M	195.43M	228.84M
Equity Growth %	7.95%	0.59%	-0.23%	-0.12%	-0.05%	1.13%	0.09%	-0.04%	0%	0.17%
Book Value per Share	6.28	5.56	3.44	2.78	2.61	5.29	4.94	5.76	4.68	5.66
Total Shareholders' Equity	85.07M	134.91M	104.08M	91.58M	87.43M	186.03M	202.93M	194.84M	195.43M	228.84M
Common Stock	21K	29K	33K	33K	34K	35K	36K	37K	38K	40K
Retained Earnings	-129.01M	-223.18M	-298.05M	-337.18M	-359.9M	-333.15M	-256.34M	-281.34M	-233.19M	-164M
Treasury Stock	-3K	0	0	0	0	0	-42.86M	-61.92M	-137.38M	-197.5M
Accumulated OCI	-1.07M	-1.33M	-1.67M	0	0	0	0	0	14K	55K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-21.57M	-75.05M	-67.02M	169.39M	27.78M	93.94M	103.56M	124.23M	274.75M	204.98M
Operating CF Margin %	-	-43.86%	-2.35%	0.6%	0.09%	0.3%	0.37%	0.27%	0.48%	0.32%
Operating CF Growth %	-0.2%	-2.48%	0.11%	3.53%	-0.84%	2.38%	0.1%	0.2%	1.21%	-0.25%
Net Income	-27.25M	-94.18M	-74.86M	-39.13M	-22.72M	26.75M	71.52M	-25M	48.16M	69.19M
Depreciation & Amortization	171K	655K	594K	110.91M	15.48M	61.55M	68.92M	138.94M	149.26M	169.16M
Stock-Based Compensation	2.21M	5.79M	7.95M	13.78M	16.53M	21.91M	24.25M	22.87M	27.14M	32.4M
Deferred Taxes	0	0	1.84M	0	0	0	-78.04M	-8.39M	-2.15M	-26.81M
Other Non-Cash Items	-28K	-34K	-34K	19.28M	-5.59M	9.03M	3.42M	8.52M	30.62M	16.02M
Working Capital Changes	3.34M	12.71M	-2.5M	64.55M	24.08M	-25.3M	13.49M	-12.71M	21.73M	-54.98M
Change in Receivables	0	-2.13M	-7.84M	-68.23M	4.99M	-10.37M	-22.52M	-21.78M	3.59M	-4.41M
Change in Inventory	0	-1.32M	-497K	219K	-1.83M	-8.27M	-2.3M	48.27M	14.17M	13.93M
Change in Payables	1.3M	5.57M	-3.42M	6.46M	0	3.77M	-5.83M	-707K	5.06M	-11.28M
Cash from Investing+	-362K	-2.98M	-990K	-24.35M	-6.44M	-373.77M	-1.94M	-573.69M	-70.81M	-287.76M
Capital Expenditures	-362K	-2.98M	-990K	-24.35M	-6.44M	-5.55M	-1.94M	-1.62M	-461K	-1.65M
CapEx % of Revenue	-	1.74%	0.03%	0.09%	0.02%	0.02%	0.01%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-2.5M	0	-18.88M	0	-368.23M	0	0	0	0
Cash from Financing+	115.99M	135.56M	33.48M	-117.2M	2.04M	286.47M	-89.3M	436.72M	-140.18M	-60.6M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-24.57M	-24.57M	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	25.07M	885K	1.81M	-127.19M	2.86M	5.08M	8.56M	8.1M	740K	-8.1M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-21.93M	-78.03M	-68.01M	145.04M	21.34M	-279.83M	101.61M	122.61M	274.29M	203.33M
FCF Margin %	-	-45.6%	-2.39%	0.52%	0.07%	-0.9%	0.37%	0.26%	0.48%	0.32%
FCF Growth %	-0.22%	-2.56%	0.13%	3.13%	-0.85%	-14.11%	1.36%	0.21%	1.24%	-0.26%
FCF per Share	-1.62	-3.22	-2.25	4.40	0.64	-7.96	2.48	3.62	6.56	5.03
FCF Conversion (FCF/Net Income)	0.79x	0.80x	0.90x	-4.33x	-1.22x	3.51x	1.45x	-4.97x	5.71x	2.96x
Interest Paid	0	0	0	0	709K	18.97M	17.61M	52.53M	73.26M	62.43M
Taxes Paid	0	0	0	0	0	483K	3M	10.4M	24.2M	52.09M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-74.84%	-85.62%	-62.65%	-39.99%	-25.39%	19.57%	36.77%	-12.57%	24.68%	32.62%
Return on Invested Capital (ROIC)	-	-	-	-	-	38.78%	4.78%	4.97%	18.4%	15.46%
Gross Margin	-	87.55%	90.89%	40.92%	34.73%	58.01%	54.4%	45.15%	57.55%	59.76%
Net Margin	-	-5504.15%	-262.91%	-13.95%	-7.66%	8.63%	25.83%	-5.39%	8.5%	10.96%
Debt / Equity	0.08x	0.03x	0.01x	0.13x	0.25x	1.43x	1.28x	3.64x	3.45x	3.75x
Interest Coverage	-61.29x	-1000.87x	-	-1.03x	-26.13x	1.95x	0.84x	0.53x	2.00x	2.30x
FCF Conversion	0.79x	0.80x	0.90x	-4.33x	-1.22x	3.51x	1.45x	-4.97x	5.71x	2.96x
Revenue Growth	-	-	1564.29%	884.73%	5.81%	4.49%	-10.69%	67.56%	22.17%	11.41%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Belbuca	-	-	-	-	126.46M	182.09M	211.27M
Belbuca Growth	-	-	-	-	-	43.99%	16.02%
Xtampza ER	-	-	-	103.71M	138.8M	177.37M	191.33M
Xtampza ER Growth	-	-	-	-	33.84%	27.79%	7.87%
Nucynta IR	-	-	-	102.22M	112.06M	108.15M	100.74M
Nucynta IR Growth	-	-	-	-	9.62%	-3.49%	-6.85%
Nucynta ER	-	-	-	70.94M	72.42M	82.65M	75.77M
Nucynta ER Growth	-	-	-	-	2.09%	14.13%	-8.33%
Symproic	-	-	-	-	12.27M	16.5M	15.1M
Symproic Growth	-	-	-	-	-	34.47%	-8.43%
Other	-	-	-	-	1.93M	-	-
Other Growth	-	-	-	-	-	-	-
Nucynta Products	-	-	-	173.16M	-	-	-
Nucynta Products Growth	-	-	-	-	-	-	-
Nucynta	211.03M	191.69M	182.03M	-	-	-	-
Nucynta Growth	-	-9.17%	-5.04%	-	-	-	-
Xtampza	-	105.01M	127.98M	-	-	-	-
Xtampza Growth	-	-	21.88%	-	-	-	-
Nucynta Ir	-	117.68M	116.32M	-	-	-	-
Nucynta Ir Growth	-	-	-1.16%	-	-	-	-
Nucynta Er	-	74.01M	65.71M	-	-	-	-
Nucynta Er Growth	-	-	-11.21%	-	-	-	-

Frequently Asked Questions

Valuation & Price

Collegium Pharmaceutical, Inc. (COLL) has a price-to-earnings (P/E) ratio of 25.2x. This suggests investors expect higher future growth.

Growth & Financials

Collegium Pharmaceutical, Inc. (COLL) reported $757.1M in revenue for fiscal year 2024.

Collegium Pharmaceutical, Inc. (COLL) grew revenue by 11.4% over the past year. This is steady growth.

Yes, Collegium Pharmaceutical, Inc. (COLL) is profitable, generating $58.4M in net income for fiscal year 2024 (11.0% net margin).

Dividend & Returns

Collegium Pharmaceutical, Inc. (COLL) has a return on equity (ROE) of 32.6%. This is excellent, indicating efficient use of shareholder capital.

Collegium Pharmaceutical, Inc. (COLL) generated $289.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Collegium Pharmaceutical, Inc. (COLL) 10-Year Financial Performance & Capital Metrics

COLL • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsPain Management

Revenue $631M +11.4%
EBITDA $339M +7.2%
Net Income $69M +43.7%
EPS (Diluted) 1.86 +44.2%
Gross Margin 59.76% +3.8%
EBITDA Margin 53.69% -3.8%
Operating Margin 26.91% -8.7%
Net Margin 10.96% +29.0%
ROE 32.62% +32.2%
ROIC 15.46% -16.0%
Debt/Equity 3.75 +8.8%
Interest Coverage 2.30 +14.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓FCF machine: 32.2% free cash flow margin
✓Momentum leader: RS Rating 83 (top 17%)
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 16.3%
✓Share count reduced 3.3% through buybacks

✗Weaknesses

✗High debt to equity ratio of 3.8x

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y16.31%

3Y31.63%

TTM26.34%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-1.1%

TTM-34.03%

EPS CAGR

10Y-

5Y-

3Y0%

TTM-30.88%

ROCE

10Y Avg-17.42%

5Y Avg14.82%

3Y Avg15.89%

Latest18.47%

Peer Comparison

Pain Management

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
COLLCollegium Pharmaceutical, Inc.	1.48B	46.90	25.22	11.41%	7.72%	21.27%	13.71%	3.75
PRFXPainReform Ltd.	3.21M	0.82	-0.03			-48.4%		0.02
PCRXPacira BioSciences, Inc.	848.72M	20.65	-9.60	3.85%	2.99%	2.95%	21.06%	0.82
APUSApimeds Pharmaceuticals US, Inc	21.76M	1.73	-15.73			-63.2%
ASRTAssertio Holdings, Inc.	71.42M	11.13	-48.39	-17.83%	-21.06%	-27.34%	36.98%	0.33

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	1.71M	28.48M	280.41M	296.7M	310.02M	276.87M	463.93M	566.77M	631.45M
Revenue Growth %	-	-	15.64%	8.85%	0.06%	0.04%	-0.11%	0.68%	0.22%	0.11%
Cost of Goods Sold+	171K	213K	2.6M	165.68M	193.66M	130.18M	126.25M	254.44M	240.6M	254.1M
COGS % of Revenue	-	0.12%	0.09%	0.59%	0.65%	0.42%	0.46%	0.55%	0.42%	0.4%
Gross Profit+	-171K	1.5M	25.88M	114.74M	103.04M	179.84M	150.62M	209.49M	326.17M	377.34M
Gross Margin %	-	0.88%	0.91%	0.41%	0.35%	0.58%	0.54%	0.45%	0.58%	0.6%
Gross Profit Growth %	-	9.76%	16.28%	3.43%	-0.1%	0.75%	-0.16%	0.39%	0.56%	0.16%
Operating Expenses+	26.91M	95.58M	101.33M	135.42M	126.79M	123.6M	132.99M	176.17M	159.21M	207.45M
OpEx % of Revenue	-	55.86%	3.56%	0.48%	0.43%	0.4%	0.48%	0.38%	0.28%	0.33%
Selling, General & Admin	18.93M	80.63M	92.76M	126.76M	116.45M	113.83M	118.96M	172.19M	159.21M	182.98M
SG&A % of Revenue	-	47.13%	3.26%	0.45%	0.39%	0.37%	0.43%	0.37%	0.28%	0.29%
Research & Development	7.97M	14.95M	8.57M	8.66M	10.34M	9.77M	9.45M	3.98M	0	0
R&D % of Revenue	-	8.74%	0.3%	0.03%	0.03%	0.03%	0.03%	0.01%	-	-
Other Operating Expenses	0	-94K	0	0	0	0	4.58M	0	0	24.47M
Operating Income+	-26.91M	-94.08M	-75.45M	-20.68M	-23.75M	56.23M	17.63M	33.32M	166.96M	169.9M
Operating Margin %	-	-54.99%	-2.65%	-0.07%	-0.08%	0.18%	0.06%	0.07%	0.29%	0.27%
Operating Income Growth %	-0.52%	-2.5%	0.2%	0.73%	-0.15%	3.37%	-0.69%	0.89%	4.01%	0.02%
EBITDA+	-26.74M	-93.43M	-74.85M	90.22M	-8.27M	117.78M	86.55M	172.26M	316.22M	339.06M
EBITDA Margin %	-	-54.6%	-2.63%	0.32%	-0.03%	0.38%	0.31%	0.37%	0.56%	0.54%
EBITDA Growth %	-0.53%	-2.49%	0.2%	2.21%	-1.09%	15.25%	-0.27%	0.99%	0.84%	0.07%
D&A (Non-Cash Add-back)	171K	655K	594K	110.91M	15.48M	61.55M	68.92M	138.94M	149.26M	169.16M
EBIT	-26.82M	-94.08M	-74.86M	-19M	-21.81M	56.46M	17.64M	34.37M	159.07M	172.54M
Net Interest Income+	0	-94K	582K	-18.44M	1.03M	-28.65M	-21M	-62.17M	-67.72M	-60M
Interest Income	0	0	582K	1.69M	1.94M	232K	12K	1.05M	15.62M	13.98M
Interest Expense	439K	94K	0	20.13M	909K	28.88M	21.01M	63.21M	83.34M	73.97M
Other Income/Expense	-348K	-94K	582K	-18.44M	1.03M	-28.65M	-21M	-62.17M	-91.23M	-71.33M
Pretax Income+	-27.25M	-94.18M	-74.86M	-39.13M	-22.72M	27.58M	-3.37M	-28.85M	75.73M	98.57M
Pretax Margin %	-	-55.04%	-2.63%	-0.14%	-0.08%	0.09%	-0.01%	-0.06%	0.13%	0.16%
Income Tax+	-91K	94K	0	0	0	830K	-74.89M	-3.85M	27.58M	29.38M
Effective Tax Rate %	1%	1%	1%	1%	1%	0.97%	-21.2%	0.87%	0.64%	0.7%
Net Income+	-27.25M	-94.18M	-74.86M	-39.13M	-22.72M	26.75M	71.52M	-25M	48.16M	69.19M
Net Margin %	-	-55.04%	-2.63%	-0.14%	-0.08%	0.09%	0.26%	-0.05%	0.08%	0.11%
Net Income Growth %	-0.52%	-2.46%	0.21%	0.48%	0.42%	2.18%	1.67%	-1.35%	2.93%	0.44%
Net Income (Continuing)	-27.25M	-94.18M	-74.86M	-39.13M	-22.72M	26.75M	71.52M	-25M	48.16M	69.19M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.01	-3.88	-2.47	-1.19	-0.24	0.76	1.86	-0.74	1.29	1.86
EPS Growth %	0.16%	-0.93%	0.36%	0.52%	0.8%	4.17%	1.45%	-1.4%	2.74%	0.44%
EPS (Basic)	-2.01	-3.88	-2.47	-1.19	-0.24	0.78	2.05	-0.74	1.60	2.14
Diluted Shares Outstanding	13.54M	24.26M	30.27M	32.95M	33.45M	35.15M	41.05M	33.83M	41.79M	40.42M
Basic Shares Outstanding	13.54M	24.26M	30.27M	32.88M	33.45M	34.41M	34.94M	33.83M	33.74M	32.27M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	96.88M	158.57M	133.48M	237.51M	255.72M	277.89M	315.54M	419.99M	537.6M	482.26M
Cash & Short-Term Investments	95.7M	153.22M	118.7M	146.63M	170.02M	174.12M	186.43M	173.69M	310.55M	162.76M
Cash Only	95.7M	153.22M	118.7M	146.63M	170.02M	174.12M	186.43M	173.69M	238.95M	70.56M
Short-Term Investments	0	0	0	0	0	0	0	0	71.6M	92.2M
Accounts Receivable	0	2.13M	9.97M	77.95M	72.95M	83.32M	105.84M	183.12M	179.53M	228.54M
Days Sales Outstanding	-	454.17	127.78	101.46	89.75	98.1	139.54	144.07	115.61	132.1
Inventory	0	1.32M	1.81M	7.82M	9.64M	15.61M	17.39M	46.5M	32.33M	35.56M
Days Inventory Outstanding	-	2.26K	255.01	17.22	18.17	43.78	50.29	66.71	49.05	51.08
Other Current Assets	558K	304K	456K	1.01M	141K	60K	27K	57K	93K	27.74M
Total Non-Current Assets+	835K	3.44M	2.08M	53.73M	50.58M	365.95M	376.53M	754.14M	605.71M	1.18B
Property, Plant & Equipment	738K	1.04M	1.83M	9.27M	20.9M	27.38M	27.14M	26.38M	22.01M	20.15M
Fixed Asset Turnover	-	1.65x	15.59x	30.24x	14.20x	11.32x	10.20x	17.59x	25.75x	31.34x
Goodwill	0	0	0	0	0	0	0	133.69M	133.86M	162.33M
Intangible Assets	0	2.1M	0	44.26M	29.5M	335.9M	268.72M	567.47M	421.71M	891.4M
Long-Term Investments	97K	97K	97K	0	0	0	0	0	0	0
Other Non-Current Assets	0	301K	161K	204K	178K	2.67M	2.63M	2.65M	1.87M	9.41M
Total Assets+	97.72M	162.02M	135.57M	291.25M	306.3M	643.84M	692.08M	1.17B	1.14B	1.66B
Asset Turnover	-	0.01x	0.21x	0.96x	0.97x	0.48x	0.40x	0.40x	0.50x	0.38x
Asset Growth %	18.2%	0.66%	-0.16%	1.15%	0.05%	1.1%	0.07%	0.7%	-0.03%	0.46%
Total Current Liabilities+	5.76M	22.93M	31.49M	187.48M	201.76M	239.45M	279.57M	433.73M	457.92M	509.51M
Accounts Payable	3.54M	9.11M	5.68M	12.15M	6.25M	10.02M	4.19M	3.49M	8.69M	3.93M
Days Payables Outstanding	7.55K	15.6K	799.48	26.77	11.77	28.08	12.11	5.01	13.19	5.65
Short-Term Debt	2.67M	2.67M	1.48M	1.64M	3.83M	47.49M	48.35M	162.5M	183.33M	64.58M
Deferred Revenue (Current)	-1000K	1000K	0	0	0	0	0	0	988K	0
Other Current Liabilities	661K	4.29M	18.21M	167.7M	5.7M	1.42M	851K	1.51M	253.91M	7.61M
Current Ratio	16.81x	6.92x	4.24x	1.27x	1.27x	1.16x	1.13x	0.97x	1.17x	0.95x
Quick Ratio	16.81x	6.86x	4.18x	1.23x	1.22x	1.10x	1.07x	0.86x	1.10x	0.88x
Cash Conversion Cycle	-	-12.89K	-416.7	91.91	96.15	113.79	177.71	205.76	151.48	177.53
Total Non-Current Liabilities+	6.88M	4.18M	7.16M	12.18M	17.11M	218.36M	209.58M	545.56M	489.96M	925.24M
Long-Term Debt	4.15M	1.48M	0	9.86M	7.67M	209.59M	201.63M	538.45M	483.84M	787.9M
Capital Lease Obligations	68K	34K	0	0	9.44M	8.77M	7.95M	7.11M	6.12M	5.54M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	676K	0	0	0	0	0	121.8M
Total Liabilities	12.65M	27.11M	31.49M	199.66M	218.87M	457.81M	489.15M	979.29M	947.88M	1.43B
Total Debt+	6.81M	4.15M	1.48M	11.5M	21.59M	266.58M	258.75M	709.17M	674.28M	859.3M
Net Debt	-88.88M	-149.08M	-117.22M	-135.13M	-148.43M	92.47M	72.32M	535.49M	435.34M	788.73M
Debt / Equity	0.08x	0.03x	0.01x	0.13x	0.25x	1.43x	1.28x	3.64x	3.45x	3.75x
Debt / EBITDA	-	-	-	0.13x	-	2.26x	2.99x	4.12x	2.13x	2.53x
Net Debt / EBITDA	-	-	-	-1.50x	-	0.79x	0.84x	3.11x	1.38x	2.33x
Interest Coverage	-61.29x	-1000.87x	-	-1.03x	-26.13x	1.95x	0.84x	0.53x	2.00x	2.30x
Total Equity+	85.07M	134.91M	104.08M	91.58M	87.43M	186.03M	202.93M	194.84M	195.43M	228.84M
Equity Growth %	7.95%	0.59%	-0.23%	-0.12%	-0.05%	1.13%	0.09%	-0.04%	0%	0.17%
Book Value per Share	6.28	5.56	3.44	2.78	2.61	5.29	4.94	5.76	4.68	5.66
Total Shareholders' Equity	85.07M	134.91M	104.08M	91.58M	87.43M	186.03M	202.93M	194.84M	195.43M	228.84M
Common Stock	21K	29K	33K	33K	34K	35K	36K	37K	38K	40K
Retained Earnings	-129.01M	-223.18M	-298.05M	-337.18M	-359.9M	-333.15M	-256.34M	-281.34M	-233.19M	-164M
Treasury Stock	-3K	0	0	0	0	0	-42.86M	-61.92M	-137.38M	-197.5M
Accumulated OCI	-1.07M	-1.33M	-1.67M	0	0	0	0	0	14K	55K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-21.57M	-75.05M	-67.02M	169.39M	27.78M	93.94M	103.56M	124.23M	274.75M	204.98M
Operating CF Margin %	-	-43.86%	-2.35%	0.6%	0.09%	0.3%	0.37%	0.27%	0.48%	0.32%
Operating CF Growth %	-0.2%	-2.48%	0.11%	3.53%	-0.84%	2.38%	0.1%	0.2%	1.21%	-0.25%
Net Income	-27.25M	-94.18M	-74.86M	-39.13M	-22.72M	26.75M	71.52M	-25M	48.16M	69.19M
Depreciation & Amortization	171K	655K	594K	110.91M	15.48M	61.55M	68.92M	138.94M	149.26M	169.16M
Stock-Based Compensation	2.21M	5.79M	7.95M	13.78M	16.53M	21.91M	24.25M	22.87M	27.14M	32.4M
Deferred Taxes	0	0	1.84M	0	0	0	-78.04M	-8.39M	-2.15M	-26.81M
Other Non-Cash Items	-28K	-34K	-34K	19.28M	-5.59M	9.03M	3.42M	8.52M	30.62M	16.02M
Working Capital Changes	3.34M	12.71M	-2.5M	64.55M	24.08M	-25.3M	13.49M	-12.71M	21.73M	-54.98M
Change in Receivables	0	-2.13M	-7.84M	-68.23M	4.99M	-10.37M	-22.52M	-21.78M	3.59M	-4.41M
Change in Inventory	0	-1.32M	-497K	219K	-1.83M	-8.27M	-2.3M	48.27M	14.17M	13.93M
Change in Payables	1.3M	5.57M	-3.42M	6.46M	0	3.77M	-5.83M	-707K	5.06M	-11.28M
Cash from Investing+	-362K	-2.98M	-990K	-24.35M	-6.44M	-373.77M	-1.94M	-573.69M	-70.81M	-287.76M
Capital Expenditures	-362K	-2.98M	-990K	-24.35M	-6.44M	-5.55M	-1.94M	-1.62M	-461K	-1.65M
CapEx % of Revenue	-	1.74%	0.03%	0.09%	0.02%	0.02%	0.01%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-2.5M	0	-18.88M	0	-368.23M	0	0	0	0
Cash from Financing+	115.99M	135.56M	33.48M	-117.2M	2.04M	286.47M	-89.3M	436.72M	-140.18M	-60.6M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-24.57M	-24.57M	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	25.07M	885K	1.81M	-127.19M	2.86M	5.08M	8.56M	8.1M	740K	-8.1M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-21.93M	-78.03M	-68.01M	145.04M	21.34M	-279.83M	101.61M	122.61M	274.29M	203.33M
FCF Margin %	-	-45.6%	-2.39%	0.52%	0.07%	-0.9%	0.37%	0.26%	0.48%	0.32%
FCF Growth %	-0.22%	-2.56%	0.13%	3.13%	-0.85%	-14.11%	1.36%	0.21%	1.24%	-0.26%
FCF per Share	-1.62	-3.22	-2.25	4.40	0.64	-7.96	2.48	3.62	6.56	5.03
FCF Conversion (FCF/Net Income)	0.79x	0.80x	0.90x	-4.33x	-1.22x	3.51x	1.45x	-4.97x	5.71x	2.96x
Interest Paid	0	0	0	0	709K	18.97M	17.61M	52.53M	73.26M	62.43M
Taxes Paid	0	0	0	0	0	483K	3M	10.4M	24.2M	52.09M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-74.84%	-85.62%	-62.65%	-39.99%	-25.39%	19.57%	36.77%	-12.57%	24.68%	32.62%
Return on Invested Capital (ROIC)	-	-	-	-	-	38.78%	4.78%	4.97%	18.4%	15.46%
Gross Margin	-	87.55%	90.89%	40.92%	34.73%	58.01%	54.4%	45.15%	57.55%	59.76%
Net Margin	-	-5504.15%	-262.91%	-13.95%	-7.66%	8.63%	25.83%	-5.39%	8.5%	10.96%
Debt / Equity	0.08x	0.03x	0.01x	0.13x	0.25x	1.43x	1.28x	3.64x	3.45x	3.75x
Interest Coverage	-61.29x	-1000.87x	-	-1.03x	-26.13x	1.95x	0.84x	0.53x	2.00x	2.30x
FCF Conversion	0.79x	0.80x	0.90x	-4.33x	-1.22x	3.51x	1.45x	-4.97x	5.71x	2.96x
Revenue Growth	-	-	1564.29%	884.73%	5.81%	4.49%	-10.69%	67.56%	22.17%	11.41%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Belbuca	-	-	-	-	126.46M	182.09M	211.27M
Belbuca Growth	-	-	-	-	-	43.99%	16.02%
Xtampza ER	-	-	-	103.71M	138.8M	177.37M	191.33M
Xtampza ER Growth	-	-	-	-	33.84%	27.79%	7.87%
Nucynta IR	-	-	-	102.22M	112.06M	108.15M	100.74M
Nucynta IR Growth	-	-	-	-	9.62%	-3.49%	-6.85%
Nucynta ER	-	-	-	70.94M	72.42M	82.65M	75.77M
Nucynta ER Growth	-	-	-	-	2.09%	14.13%	-8.33%
Symproic	-	-	-	-	12.27M	16.5M	15.1M
Symproic Growth	-	-	-	-	-	34.47%	-8.43%
Other	-	-	-	-	1.93M	-	-
Other Growth	-	-	-	-	-	-	-
Nucynta Products	-	-	-	173.16M	-	-	-
Nucynta Products Growth	-	-	-	-	-	-	-
Nucynta	211.03M	191.69M	182.03M	-	-	-	-
Nucynta Growth	-	-9.17%	-5.04%	-	-	-	-
Xtampza	-	105.01M	127.98M	-	-	-	-
Xtampza Growth	-	-	21.88%	-	-	-	-
Nucynta Ir	-	117.68M	116.32M	-	-	-	-
Nucynta Ir Growth	-	-	-1.16%	-	-	-	-
Nucynta Er	-	74.01M	65.71M	-	-	-	-
Nucynta Er Growth	-	-	-11.21%	-	-	-	-

Frequently Asked Questions

Valuation & Price

Collegium Pharmaceutical, Inc. (COLL) has a price-to-earnings (P/E) ratio of 25.2x. This suggests investors expect higher future growth.

Growth & Financials

Collegium Pharmaceutical, Inc. (COLL) reported $757.1M in revenue for fiscal year 2024.

Collegium Pharmaceutical, Inc. (COLL) grew revenue by 11.4% over the past year. This is steady growth.

Yes, Collegium Pharmaceutical, Inc. (COLL) is profitable, generating $58.4M in net income for fiscal year 2024 (11.0% net margin).

Dividend & Returns

Collegium Pharmaceutical, Inc. (COLL) has a return on equity (ROE) of 32.6%. This is excellent, indicating efficient use of shareholder capital.

Collegium Pharmaceutical, Inc. (COLL) generated $289.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.